PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Meßner, M.* ; Schmitt, S.* ; Ardelt, M.A.* ; Fröhlich, T.* ; Müller, M.* ; Pein, H.* ; Huber-Cantonati, P.* ; Ortler, C.* ; Koenig, L.M.* ; Zobel, L.* ; Koeberle, A.* ; Arnold, G.J.* ; Rothenfußer, S.* ; Kiemer, A.K.* ; Gerbes, A.L.* ; Zischka, H. ; Vollmar, A.M.* ; Pachmayr, J.*

Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.

FASEB J. 34, 11860-11882 (2020)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Sorafenib represents the current standard of care for patients with advanced-stage hepatocellular carcinoma (HCC). However, acquired drug resistance occurs frequently during therapy and is accompanied by rapid tumor regrowth after sorafenib therapy termination. To identify the mechanism of this therapy-limiting growth resumption, we established robust sorafenib resistance HCC cell models that exhibited mitochondrial dysfunction and chemotherapeutic crossresistance. We found a rapid relapse of tumor cell proliferation after sorafenib withdrawal, which was caused by renewal of mitochondrial structures alongside a metabolic switch toward high electron transport system (ETS) activity. The translation-inhibiting antibiotic tigecycline impaired the biogenesis of mitochondrial DNA-encoded ETS subunits and limited the electron acceptor turnover required for glutamine oxidation. Thereby, tigecycline prevented the tumor relapse in vitro and in murine xenografts in vivo. These results offer a promising second-line therapeutic approach for advanced-stage HCC patients with progressive disease undergoing sorafenib therapy or treatment interruption due to severe adverse events.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.966
1.102
1
7
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Antibiotics ; Electron Acceptor Auxotrophy ; Mitochondrial Biogenesis ; Sorafenib Resistance ; Tumor Relapse; Cancer-cells; Oxidative-phosphorylation; Mitochondrial Biogenesis; Antitumor-activity; Therapy; Proliferation; Translation; Inhibition; Mitophagy; Receptor
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 0892-6638
e-ISSN 1530-6860
Zeitschrift FASEB Journal
Quellenangaben Band: 34, Heft: 9, Seiten: 11860-11882 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort Bethesda, Md.
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Molecular Toxicology and Pharmacology (TOX)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-505200-003
DOI 10.1096/fj.202001128R
WOS ID WOS:000548010700001
Scopus ID 85089749642
PubMed ID 32652772
Erfassungsdatum 2020-07-28
[➜Korrektur melden]